PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: MRC Technology

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

MRC and MRC Technology Announce New Centre for the Discovery of Novel Drugs - A major centre to fast-track the discovery and development of novel drugs will be created by the Medical Research Council (MRC) and MRC Technology (MRCT)
MRC and MRC Technology Announce New Centre for the Discovery of Novel Drugs

 

NewswireToday - /newswire/ - London, United Kingdom, 2009/04/02 - A major centre to fast-track the discovery and development of novel drugs will be created by the Medical Research Council (MRC) and MRC Technology (MRCT).

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The MRCT Centre for Therapeutics Discovery (CTD), based in London, will build on the existing work of the MRCT Drug Discovery Group, expanding current capability and capacity to provide the UK with a national drug discovery resource with the critical mass to progress high quality projects towards clinical benefit. Promising molecules and antibodies will be taken down the path to clinical application by a partnership between the CTD, academic scientists and industry. It will commence work immediately.

Building on the wealth of high quality research in the UK, the CTD will collaborate with scientists in universities and MRC units to develop drug discovery projects. These will target diseases for which there is significant unmet need. The centre will apply state of the art computational and medicinal chemistry to produce ‘drug-like’ molecules with potential to become therapies.

The CTD will also focus on developing novel antibody therapies, bringing to bear its world-class expertise in antibody humanisation technology. Already, this capability has been successfully exploited to partner several therapeutic antibodies identified from within the MRC research base. It’s also enabled biopharmaceutical companies to launch two antibody-based drugs (the fastest growing therapeutic area in the industry) onto the market and progress several more into the clinic.

This initiative will enable UK scientists to tap into MRC’s recently announced Developmental Pathway Funding Scheme (DPFS) and collaborate with a high quality drug discovery capability whilst retaining existing IP ownership.

Sir Leszek Borysiewicz, MRC Chief Executive, said: “This centre of national excellence, in forming partnerships with academia, will provide a focus of knowledge and expertise. The initiative will benefit patients in the UK and around the world. It will also support innovation and provide a training ground for the next generation of scientists across Britain. It is these types of projects which represent the seed corn of the future UK economy by enhancing the UK’s leadership position in the scientific and technical disciplines of early stage medicine discovery.”

Dr David Tapolczay, MRCT’s CEO explained: “For the first time UK academics will have a dedicated centre with which to collaborate and progress their science to deliver tangible clinical benefit. In so doing, this initiative will help the UK to retain it’s world-leading reputation for innovation in drug discovery.”

Dr Justin Bryans, Director of Centre for Therapeutics Discovery at MRCT, commented: “We want to work with the best academic scientists and develop the impressive drug discovery knowledge base that exists in the UK today. The CTD will offer an expertise in drug discovery that can be accessed by UK academics to translate their projects towards clinical benefit, and will provide a forum for education and training in the field of medicines research. Skilled jobs in medicinal chemistry and biosciences will be created, and partnering our products with pharma and biotech companies worldwide will increase the value of the basic research that we support.”

The Centre for Therapeutics Discovery will have an operating budget of £6million, which will be secured from a number of sources, including MRC translational funding and royalty income from any products. The CTD will commercialise its products, but profits will be reinvested.

About MRC
The Medical Research Council (mrc.ac.uk) supports the best scientific research to improve human health. Its work ranges from molecular level science to public health medicine and has led to pioneering discoveries in our understanding of the human body and the diseases which affect us all.

About MRC Technology (MRCT)
MRCT (mrctechnology.org) translates cutting edge scientific discoveries into commercial products, two of which (Tysabri and Actemra) are already on the market. The MRCT Centre for Therapeutics Discovery works closely with the MRCT Intellectual Property and Business Development Division and is rigorous in the selection of well-defined and characterised targets, and considers novelty, validation and ‘druggability’. In addition, the group works on targets where there is a clear strategy for progression and development.

About Developmental Pathway Funding Scheme (DPFS)
The Developmental Pathway Funding Scheme (DPFS) is a new, rigorously assessed, funding scheme set up by the MRC to help strengthen the translation of fundamental research towards patient benefit. The scheme – which will not fund basic discoveries – will support the development of novel therapies, interventions and diagnostics, and the research tools used in the development of therapies, interventions or diagnostics. Projects should target significant and unmet health needs.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: MRC Technology

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


MRC and MRC Technology Announce New Centre for the Discovery of Novel Drugs

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Jonathan McGee - MRC.AC.uk 
+44(0)20 8906 7127 ctd[.]tech.mrc.ac.uk
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any MRC Technology securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From MRC Technology / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Triggr & Bloom

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)